

USFDA Successfully Completes Inspection At Indoco Remedies Mumbai API Facility

Written By: Ruchika Sharma | Medically Reviewed By: Dr. Kamal Kant Kohli Published On 19 Sept 2025 3:58 PM | Updated On 19 Sept 2025 3:58 PM



Mumbai: Indoco Remedies Limited has announced that the United States Food and Drug Administration (USFDA) successfully completed inspection of its Active Pharmaceutical Ingredients (API) manufacturing facility at Patalganga, Navi Mumbai.

The inspection concluded with zero form 483 observations.

"This successful USFDA inspection is a testament to the strong quality culture and compliance in every process and every product. We remain committed to strengthening our systems to deliver safe and efficacious medicines across the globe," said Aditi Panandikar, Managing Director, Indoco Remedies Limited.

Read also: Indoco Remedies gets USFDA nod for venous thromboembolism drug Rivaroxaban

Indoco is a fully integrated, research-oriented pharmaceutical company with a global presence. The Company's turnover is US\$ 180 million with a human capital of over 6000 employees, including over 400 skilled scientists and field staff.

Read also: Indoco Remedies secures USFDA approval for Allopurinol Tablets to lower high uric acid levels in blood

The Company has 11 manufacturing facilities, 7 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 106 million prescriptions annually from over 2,40,000 doctors belonging to various specialties. Indoco has 10 domestic marketing divisions, a brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Diabetics, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Aloja, Glychek, Kidodent, Subitral, Rexidin, MCBM 69, Methycal, Dropizin, Noxa, Homide, Cal-Aid, Ninaf, Cital- Uti, Otorex, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.